EN DE
Watch Sagimet Biosciences Inc. Series A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sagimet Biosciences Inc. Series A (SGMT) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Sagimet Biosciences Inc. Series A stock $7.84, price $10.13, that is 22.6% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

SB Sagimet Biosciences Inc. Series A logo Thin data Nov 15, 2026

Sagimet Biosciences Inc. Series A

SGMT · US

Expensive (fair value 23% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Recent news mixed 
Insiders sold $4.5M (6M) 
Fair value $7.84 · Overvalued 
Quality 37/100 
Weak Growth 
Negative free cash flow 
Trails peers (1/6) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Sagimet Biosciences Inc. Series A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.42 $1.90 Fair Value $7.84 Jul 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

40‑month range $1.90 – $18.42 · fair‑value band $5.88 – $9.80 · the $10.13 price screens above the $7.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Sagimet Biosciences Inc. Series A in your weekly email

Every Wednesday you see whether Sagimet Biosciences Inc. Series A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.

Show moreShow less

The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.

Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Stock analysis

Sagimet Biosciences Inc. Series A (SGMT) currently trades at $10.13, while our estimate is $7.84, 23% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.88 (bear) to $9.80 (bull), the price of $10.13 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Sagimet Biosciences Inc. Series A reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$51.0M in FY2025.

Key figures

Market cap $729M Small · EPS (TTM) $−1.18 · Return on equity −29.5% · Return on assets (EBIT) −49.8% (5-year average) · Free cash flow −$45.7M · Net cash $109M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 123% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −23%, SGMT screens richer than that median.

Fair Value

Bear $5.88 Fair Value $7.84 Bull $9.80
Price $10.13 · Downside -22.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 63
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 61
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 75
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $4.5M and none bought.

  • SaleGeorge KembleDirector4× since Nov 20, 2025: 427,725 shares, avg. $9.87$4.2MAug 14, 202610b5-1 plan
  • SaleElizabeth RozekChief Legal & Admin. Officer2× since Feb 10, 2026: 13,167 shares, avg. $7.28$95,883Jul 20, 2026
  • SaleDavid HappelPresident & CEO, Director2× since Feb 10, 2026: 76,152 shares, avg. $7.38$561,897Jul 20, 2026
  • SaleEduardo Bruno MartinsChief Medical Officer3,640 shares at $5.36$19,510Feb 10, 2026
  • SaleThierry ChaucheChief Financial Officer1,312 shares at $5.36$7,032Feb 10, 2026

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SGMT screens overvalued: fair value 23% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (58 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Sagimet Biosciences Inc. Series A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −22.6% · Above median
Profitability
Return on assets −43.8% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.54× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)3 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs SGMT
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs SGMT
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs SGMT
argenx SE ARGX $950.95 $908.40 −4% vs SGMT
CSL Limited CSL A$199.55 A$186.49 −7% vs SGMT
Moderna, Inc MRNA $215.27 $135.64 −37% vs SGMT
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs SGMT
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs SGMT
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs SGMT
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs SGMT

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sagimet Biosciences Inc. Series A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sagimet Biosciences Inc. Series A Fair Value". https://www.fairvalue-calculator.com/stock/SGMT

Frequently asked questions

Is Sagimet Biosciences Inc. Series A (SGMT) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $7.84 versus a price of $10.13, about 23% lower (overvalued).
What is the fair value of SGMT?
Our estimate for Sagimet Biosciences Inc. Series A is $7.84 (as of Nov 15, 2026), built from audited fundamentals. The current price: $10.13.
What is the quality score of SGMT?
Sagimet Biosciences Inc. Series A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sagimet Biosciences Inc. Series A (SGMT)?
Our calculated price target is the estimate of $7.84 (as of Nov 15, 2026). Cautious scenario $5.88, optimistic scenario $9.80. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sagimet Biosciences Inc. Series A stock forecast for 2026?
Our estimate puts fair value at $7.84, about 23% lower versus a price of $10.13 (overvalued). Cautious scenario $5.88, optimistic scenario $9.80. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Sagimet Biosciences Inc. Series A (SGMT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sagimet Biosciences Inc. Series A it is $7.84 per share (as of Nov 15, 2026), against a price of $10.13.
Is Sagimet Biosciences Inc. Series A stock overvalued or undervalued in 2026?
As of Nov 15, 2026, SGMT trades above its calculated fair value: price $10.13, fair value $7.84, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SGMT?
No. The price is what the market pays today ($10.13); the fair value is what the company's own numbers justify ($7.84). For Sagimet Biosciences Inc. Series A the two are $2.29 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sagimet Biosciences Inc. Series A worth?
The market values Sagimet Biosciences Inc. Series A at about $729M (market capitalisation, as of Nov 15, 2026). Per share that is $10.13; our models calculate a fair value of $7.84 per share.
What do the bullish and bearish scenarios say about SGMT?
Our models span a range for Sagimet Biosciences Inc. Series A: cautious scenario $5.88, base $7.84, optimistic $9.80 per share (as of Nov 15, 2026, price $10.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sagimet Biosciences Inc. Series A (SGMT)?
Balance-sheet figures for Sagimet Biosciences Inc. Series A (as of Nov 15, 2026): return on equity −29.5%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is SGMT from its 52-week high?
Sagimet Biosciences Inc. Series A trades at $10.13, about 11% below its 52-week high of $11.41 and 123% above the low of $4.55 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $7.84 is for.
Which stocks are comparable to Sagimet Biosciences Inc. Series A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sagimet Biosciences Inc. Series A stock attractive at the current price?
The data as of Nov 15, 2026: price $10.13, calculated fair value $7.84 (−23%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Sagimet Biosciences Inc. Series A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sagimet Biosciences Inc. Series A (SGMT)?
The closing price on Nov 16, 2026 was $10.13. Our estimate is $7.84, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sagimet Biosciences Inc. Series A right now?
The price sits above even our optimistic bull case ($9.80). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sagimet Biosciences Inc. Series A

How large is the market capitalisation of Sagimet Biosciences Inc. Series A (SGMT)?
The market capitalisation of Sagimet Biosciences Inc. Series A is $729M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sagimet Biosciences Inc. Series A (SGMT)?
Earnings per share at Sagimet Biosciences Inc. Series A are $−1.18. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sagimet Biosciences Inc. Series A (SGMT)?
The return on equity (ROE) of Sagimet Biosciences Inc. Series A is −29.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sagimet Biosciences Inc. Series A (SGMT)?
On an EBIT basis the return on assets of Sagimet Biosciences Inc. Series A is −49.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Sagimet Biosciences Inc. Series A (SGMT) generate?
The free cash flow of Sagimet Biosciences Inc. Series A is −$45.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sagimet Biosciences Inc. Series A (SGMT) hold?
Sagimet Biosciences Inc. Series A holds more cash than debt, $109M net (balance sheet 30 Sep 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sagimet Biosciences Inc. Series A in the live analysis

One click puts Sagimet Biosciences Inc. Series A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.